Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

PHASE4RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions

Coronary Artery Disease

Interventions

DRUG

Rosuvastatin

Pharmacotherapy for reduction in LDL cholesterol level

DRUG

Colchicine

Pharmacotherapy for inflammation inhibition

DRUG

Placebo

Capsule with sugar pill that mimics active study drugs

Trial Locations (1)

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Massachusetts General Hospital

OTHER